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Objectives: 
d,l-threo-methylphenidate HCl (d,l-MPH) is the most common treatment of attention deficit 
hyperactivity disorder (ADHD). A previous report showed placebo-controlled efficacy for the purified d-
isomer (dexmethylphenidate hydrochloride, d-MPH, Focalin™) with a 2:1 potency compared to dl, and 
suggested a 6-hour duration of action. This study complements that report by studying the effect of 
placebo-controlled discontinuation and retesting the duration of action. 
Methods: 
A 6-week, open-label titration of d-MPH (2.5–10 mg twice-a-day) was followed by a double-
blind, placebo-controlled, 2-week withdrawal study of responders. 
Results: 
In the open titration, 82% of the 89 enrolled patients achieved a Clinical Global Impression—
Improvement (CGI-I) rating of much or very much improved. Only 5 patients discontinued for adverse 
events. Seventy-five patients continued into the placebo-controlled discontinuation. For the randomly 
assigned d-MPH (n = 35) and placebo (n = 40) groups, mean ages, respectively, were 10.1 ± 2.9 and 9.9 ± 
2.7 years, 86% and 78% were male, and 70.6% and 80.0% took the ceiling dose of 10 mg twice-daily, 
respectively. Each group had 80% combined-type ADHD and 20% inattentive type. By the end of the 2-
week, placebo-masked withdrawal, significantly more placebo patients (24 of 39) than d-MPH continuers 
(6 of 35) relapsed (61.5% versus 17.1%, p = 0.001). Compared to d-MPH continuers, placebo patients 
deteriorated significantly more in the 2-week period on teacher ratings of the 18 ADHD symptoms rated 0–
3 (p = 0.028), the 3 p.m. and 6 p.m. parent ADHD symptom ratings (p = 0.0026 and p = 0.0381, 
respectively), and clinic (2–3 p.m.) and home (6 p.m.) Math Tests (p = 0.024 and p < 0.0001, respectively). 
The 6 p.m. scores replicated the significant effect at 6 hours reported in the previous study. 
Conclusions: 
d-MPH is safe, tolerable, and effective, with a 6-hour duration of effect suggested by the 
significant difference from placebo at 6 hours on a double-blind discontinuation. 
Introduction 
Attention deficit hyperactivity disorder (ADHD) is a common neurobehavioral syndrome 
affecting approximately 3%–5% of school-aged children in the United States (American 
Psychiatric Association 1994; Jadad et al. 1999; National Institutes of Health 1998). With 
persistent core symptoms of developmentally inappropriate overactivity, distractibility, 
inattention, and impulsivity, it impairs social, academic, and occupational functioning (American 
Psychiatric Association 1994). Stimulant medications (methylphenidate and amphetamine) are 
first-line pharmacotherapy for ADHD (American Academy of Pediatrics 2001; Dulcan 1997; 
Jadad et al. 1999), producing rapid improvement in behavior and attentiveness, generally 
followed by improved academic performance (Elia et al. 1999; Goldman et al. 1998; National 
Institutes of Health 1998). For decades, the most widely prescribed stimulant has been racemic 
threo-methylphenidate (d,l- MPH). Methylphenidate (MPH) is stereoisomeric in two ways: it has 
threo and erythro enantiomers, each of which has a dextro and levo enantiomer, making 4 
possible stereoisomers. Racemic (d,l) threo-methylphenidate has been available for over 45 years 
in the United States and is considered one of the pharmacologic treatments of choice for ADHD. 
The racemic mixture of d-threo and l-threo enantiomers undergoes enantioselective metabolism 
without racemization after oral dosing in humans (Kimko et al. 1999; Srinivas et al. 1992). Both 
the pharmacological properties (Patrick et al. 1987) and the clinical efficacy of d,l-threo-MPH 
reside in the d-threo enantiomer, with improvement in sustained attention attributed to treatment 
with equimolar doses of d-MPH and d,l-MPH, but not with l-MPH (Srinivas et al. 1992). 
d-MPH (Focalin™) is a chirally pure refinement of d,l-MPH. Because d-MPH does not 
racemize after oral administration (Srinivas et al. 1992), administration of doses lower than 
currently used for the racemate may be possible without reducing efficacy or increasing adverse 
events (AEs). In another phase III trial (Wigal et al. 2004), d-MPH was significantly more 
effective than placebo in treating ADHD symptoms. Compared to d,l-MPH doses containing the 
same amount of d-MPH, d-MPH showed similar efficacy and a nominally longer duration of 
action: at 6 hours postdose, d-MPH but not d,l-MPH was still significantly better than placebo on 
parent-rated ADHD symptoms and on a timed arithmetic test (Wigal et al. 2004). No AEs unique 
to chirally pure d-MPH were reported. 
This study was intended to complement the above study. The primary aim of this study 
was to determine the placebo-controlled efficacy of twice-daily dosing with d-MPH in sustaining 
a reduction of ADHD symptoms through the 7th and 8th week in children who were responding 
to d-MPH. A secondary aim was to confirm the 6-hour duration of efficacy found in the placebo-
controlled comparison to d,l-MPH (Wigal et al. in press). 
Methods 
Subjects 
Subjects were children and adolescents 6–17 years of age enrolled in school (minimum, 
Grade 1) who met the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th 
edition (DSM-IV) for any of the three ADHD subtypes (predominantly inattentive, 
predominantly hyperactive/impulsive, or combined) (American Psychiatric Association 1994). 
Diagnosis was confirmed by the Diagnostic Interview Schedule for Children version IV (DISC-
IV) administered to parents (Shaffer et al. 2000). Concurrent treatment with other psychoactive 
medication was not allowed, and patients were withdrawn from other ADHD medications during 
screening and for 48 hours before baseline. Patients needed to be within 30% of normal body 
weight and able to participate for the full 8 weeks. 
Exclusion criteria included history or evidence of cardiovascular, renal, respiratory (other 
than asthma/allergy), endocrine, or immune system disease; history of substance abuse; 
hypersensitivity to d,l-MPH or other stimulants; treatment with any investigational drug within 
30 days of screening; other significant central nervous system disorders; and treatment with 
antidepressants, neuroleptics/antipsychotics, mood stabilizers, anticonvulsants, beta blockers, 
alpha2 agonists, other stimulants, thyroid medications, chronic oral steroids, or 
sedatives/hypnotics. 
Informed consent was obtained from the parent/guardian, and verbal or written assent 
was obtained from the participant. The protocol was approved by each center’s institutional 
review board and carried out according to the Declaration of Helsinki. 
Subjects were prematurely terminated if AEs or classroom behavior became intolerable. 
In addition, if therapeutic response, defined as Clinical Global Impression—Improvement (CGI-
I) of 1 or 2, was not evident with d-MPH at 20 mg daily during the initial 6-week, open-label 
phase, the participant was considered a therapeutic failure and discontinued. 
Study Design 
This 7-center U.S. study (Table 1) consisted of a 6-week, open-label, dose-titration phase 
(Part A) and a 2-week, double-blind, randomized, placebo-controlled withdrawal (Part B). An 
open-label extension of up to 44 weeks (Part C) will be pooled with two other open-label studies 
for analysis and reporting. 
After an initial screening (Visit 1), which included a medical history, physical 
examination, clinical laboratory studies, and recording of concomitant medications, eligible 
children entered a 6-week, open-label, dose-titration phase. Baseline evaluations were completed 
and d-MPH titration was initiated at Visit 2, after all other medications for ADHD were 
discontinued for at least 48 hours. d-MPH was initiated in doses ranging from 2.5 to 10 mg 
twice-daily, depending on individual subjects’ prior medication experience. Children who had 
received d,l-MPH began with half their total daily d,l-MPH dose administered as d-MPH, but not 
more than 20 mg/day; those who had not previously received d,l-MPH started d-MPH at 2.5 mg 
twice daily. 
During the first 4 weeks, d-MPH was titrated to one of three benchmarks: 1) a maximum 
of 20 mg/day, 2) dose-limiting AEs, or 3) achievement of a CGI-I score of 1 or 2: “very much 
improved” or “much improved.” Even if a CGI-I of 1 or 2 was not achieved by the 4th week, 
subjects continued on the dose administered in week 4 for the remainder of Part A to stabilize the 
response. 
Subjects were seen weekly for efficacy assessments (Table 1); physical examinations 
relevant to any complaint; and review of concomitant medications, concurrent illness, and other 
AEs. 
In the interval between visits, teachers rated children’s symptoms of ADHD twice a week 
in the afternoon using the Swanson, Nolan, and Pelham (SNAP)-ADHD Rating Scale (Swanson 
et al. 2001). On Saturdays and Sundays, parents rated their child’s ADHD symptoms on the 
SNAP-ADHD twice-daily, at 3 p.m. (approximately 3 hours after the second d-MPH dose) for 
the day and at 6 p.m. for the previous 2 hours. During the final 2 weeks of Part A, a timed Math 
Test was also administered at home on Saturday and Sunday approximately 6 hours after the 
second daily d-MPH dose, as was done at the afternoon clinic visit. 
For the 2-week, double-blind withdrawal phase (Part B), subjects having a CGI-I of 1 or 
2 at the end of Part A were randomized to either continue on d-MPH at the same dose as during 
the final 2 weeks of Part A or to receive placebo. (Those who had not achieved a CGI-I of 1 or 2 
were dropped from the study and treated clinically.) At weekly visits, the CGI-I and Math Tests 
were administered, along with a physical examination and review of concomitant medications, 
concurrent illness, and AEs. Between visits, the Teacher and Parent SNAP-ADHD ratings and 
weekend 6 p.m. Math Test were completed, as in Part A. 
Duration 2-14 days 6 weeks 2 weeks 
Phase of study Screening period 
Part A: 
Open-label dose-titration phase 
Part B: 
Double-blind 
withdrawal 
phase Titrate Optimal dose 
Visit* 1 2 3 4 5 6 7 8† 9 10‡ 
Begin Study Week 1 2 3 4 5 6 7 8  
Weeks on Treatment 0 1 2 3 4 5 6 7 8 
CGI-S  ◆      ◆   
CGI-I  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ 
Math Test (Home) 6 p.m.      ◆ ◆ ◆ ◆ 
Math Test (Clinic) 3 p.m.      ◆ ◆ ◆ ◆ 
Teacher SNAP-ADHD§  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ 
Parent SNAP-ADHD||  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ 
Table 1.Study design and schedule of outcome measures 
Results of a 7-center, 8-week study consisting of a 6-week open-label, dose-titration phase (Part A) and a 2-week, double-
blind, randomized, placebo-controlled withdrawal (Part B). 
CGI-S, Clinical Global Impression—Severity of Illness Scale; CGI-I, Clinical Global Impression—Improvement Scale; 
SNAP-ADHD, Swanson, Nolan, and Pelham—Attention Deficit Hyperactivity Disorder symptom scale. 
*Visits were to occur within 0.5–3 hours of the child ingesting the study medication. The interval between Visits 1 and 2 
was preferably 4–7 days; however, it could be 2–14 days. All other visits were ±2 days when weekly. 
†Randomization occurred at the end of Visit 8. 
‡The end of Part B was Visit 10, or Visit 9 if patient stopped study after Visit 9. 
§To be recorded twice weekly by the teacher at school in the afternoon during the week preceding the listed clinic visit. 
||To be recorded twice by the parent on the weekend preceding the listed clinic visit. 
Efficacy Measures 
The primary efficacy variable was the percentage of treatment failures at the end of Part 
B, defined as a CGI-I score of 6 or 7 (“much worse” or “very much worse”) relative to Visit 8 
(week 6, the end of the initial open treatment). The primary duration-of-effect variable was the 
objective 6 p.m. Math Test, the only measure specific to 6 p.m. It is more relevant than the 
parent ratings made at the same time both because it is more objective and because it is more 
specific to the exact time: Parent ratings were influenced by behavior over the preceding 2 hours. 
Secondary efficacy variables included the change from baseline (end of titration) to the end of 
Part B in the Teacher and Parent SNAP ratings and mid-afternoon, clinic-based Math Test 
scores. 
The CGI-I, completed by the investigator, uses a 7-point scale as an index of change in 
the child’s behavioral symptoms, ranging from “very much improved” (1) to “very much worse” 
(7). CGI-I scores were based on scores from at least one Teacher SNAP-ADHD, one Parent 3 
p.m. SNAP-ADHD, and an interview with the parent and child, which, during Part A, were 
compared to the same data from the original baseline and, during Part B, were compared to the 
same data from the end of Part A, after the child had been on the effective dose for at least 2 
weeks. The CGI—Severity (CGI-S) was administered twice during Part A, initially to verify that 
the patient’s illness severity warranted pharmacological treatment. The CGI-S is a 7-point scale, 
ranging from “normal, not at all [ill]” (1) to “among the most severely ill patients” (7) (Guy 
1976). 
The SNAP-ADHD rating scale consists of 18 questions similar in wording to the 
diagnostic symptoms for ADHD in the DSM-IV (Gaub and Carlson 1997; www.adhd.net). 
Parents and teachers completed evaluation forms. For each question, the teacher or parent 
indicated whether the symptom described the child “not at all” (0) to “very much” (3). Weekly 
scores were computed as the average per item, averaged separately for the Teacher and Parent 
SNAP-ADHD. 
The Math Test consisted of 300 problems (60 problems at each grade level, 1 through 5). 
Patients had 10 minutes to complete the test (without encouragement), which was designed so 
that all children could solve at least some problems and no one was likely to finish all. The score 
was the number of correct answers. Baseline scores were derived from an average of scores on 
Visits 7 and 8 (last 2 weeks of the initial Part A open treatment). Treatment scores were averages 
of Visits 9 and 10 (double-blind weeks) or just Visit 9 if the patient discontinued. Results were 
interpreted as the ability to focus and perform academic seat work, and not mathematical 
aptitude (see Swanson et al. 1998 for use of the math test [PERMP, or permanent product] as an 
objective measure of time-course effects). 
Safety assessments 
The safety of d-MPH was assessed by monitoring AEs and changes from baseline in vital 
signs, physical examination, and clinical laboratory parameters throughout the study. Also 
recorded were the number of children who discontinued because of AEs, the incidence and 
severity of each AE, action taken, and relationship to study drug. 
Laboratory evaluations included complete blood count with hemoglobin and hematocrit; 
serum chemistries, including liver function tests, glucose, electrolytes, albumin, total protein, 
total bilirubin, uric acid, and alkaline phosphatase; and urinalysis, including ketones, bilirubin, 
glucose, and protein. A urine pregnancy test was administered at the final study visit to females 
who reached menarche. 
Study drug 
To maintain blinding, d-MPH was available in tablet strengths of 2.5, 5, and 10 mg, each 
identical in appearance to a matching placebo. Patients received a total d-MPH dose ranging 
from 2.5 to 10 mg twice daily. 
Study drug (or placebo) was dispensed in bottles containing a weekly supply, labeled for 
use at “Home” and “School,” with the strength designated “A,” “B,” or “C.” The initial dose was 
2.5 mg twice-daily for treatment-naïve patients and one half the d,l-MPH dose (5 or 10 mg) 
twice-daily for previously treated patients. In Part B, patients/guardians and medical personnel 
were blinded to the drug. Parents/ guardians were instructed to administer a single tablet between 
7 a.m. and 8 a.m. and a single tablet between 11:30 a.m. and 12 p.m. 
Statistical methods 
Analysis of efficacy parameters used the intent- to-treat sample: Patients who received d-
MPH and had a Part B baseline efficacy evaluation and at least one postbaseline assessment. 
Except for the Math Test, low values indicated greatest therapeutic benefit. Analysis of variance 
(ANOVA) blocked by site was used for between-group comparisons of continuous efficacy 
variables and baseline demographics. Categorical and/or ordinal efficacy variables and 
demographic baseline variables between groups were assessed with Cochran Mantel Haenszel 
tests stratified by site. Categorical variables, assumed a priori to have very small counts in some 
cells, were evaluated by a Fisher’s Exact test. 
Safety evaluations included all patients who received at least 1 d-MPH dose. Analyses of 
AEs, laboratory values, and vital signs used descriptive rather than inferential statistics. 
Results 
Patients 
Of 116 patients screened for enrollment, 89 patients (76.7%) passed all screening, 
qualified at baseline, and entered Part A (72 boys [80.9%] and 17 girls [19.1%]). ADHD 
Combined Type was the most common (80%), with 71.9% of patients treatment-naïve. CGI-S 
scores at baseline showed significant impairment: 1 patient was borderline, approximately half  
(51.7%) were moderate, and the others were markedly (29.2%) or severely (18.0%) ill. 
Thirteen of 89 patients discontinued treatment during Part A because of therapeutic 
failure (4 patients), AEs (4), lost to follow-up (3), withdrawal of consent (1), or protocol 
violation (1). Because nonresponders dropped out in the first 6 weeks, the 76 subjects who 
successfully completed Part Aappeared to make an 85.3% response rate, but because of missing 
data, only 73 responders had CGI-I ratings of 1 or 2, making for a technical response rate of 
82%. Of these 76 responders, 75 entered Part B; the other patient discontinued before Part B 
because of AEs (headache, insomnia, and rash). Two patients (1 patient per treatment group) did 
not complete Part B; 1 patient switched to open-label d-MPH after 1 week because of poor 
behavior and 1 patient received only one assessment during 9 days of double-blind treatment. 
Demographic and baseline clinical characteristics of patients entering Part B are listed in 
Table 2. Treatment groups were similar in age, gender, ethnicity, and ADHD type. There were 
slightly more treatment-naïve patients receiving d-MPH than placebo. By Part B (i.e., following 
6 weeks of open treatment with d-MPH), most patients demonstrated mild-to-no ADHD 
behavioral symptoms (88.6% of patients subsequently randomized to d-MPH; 87.5% of patients 
subsequently randomized to placebo). Part B baseline scores on outcome measures were similar 
between groups. Part B baseline use of concomitant medications (antihistamines, nonsteroidal 
anti-inflammatory agents, multivitamins, nasal decongestants, or other analgesics or antipyretics) 
was also similar, with use in 34.3% of d-MPH patients and 40.0% of placebo patients. 
Characteristic 
d-MPH Placebo 
n = 35 n = 40 
Age, years   
Mean ± SD 10.1 ± 2.9 9.9 ± 2.7 
Range 6-16 6-16 
Gender, n (%)   
Male 30 (85.7) 31 (77.5) 
Female 5 (14.3) 9 (22.5) 
Ethnicity, n (%)   
Caucasian 28 (80.0) 30 (75.0) 
African-American 5 (14.3) 5 (12.5) 
Hispanic 2 (5.7) 5 (12.5) 
ADHD type, n (%)   
Inattentive 7 (20.0) 8 (20.0) 
Combined (Inattentive + Hyperactive/Impulsive) 28 (80.0) 32 (80.0) 
Stimulant naïve, n (%) 29 (82.9) 25 (62.5) 
CGI-S, n (%)   
Normal, not at all ill 8 (23.5) 5 (12.5) 
Borderline mentally ill 15 (44.1) 15 (37.5) 
Mildly ill 8(23.5) 15 (37.5) 
Moderately ill 3 (8.8) 4 (10.0) 
Markedly ill 0 1 (2.5) 
Severely ill 0 0 
Extremely ill 0 0 
Teacher SNAP-ADHD, Mean ± SD* 0.7 ± 0.7 0.7 ± 0.7 
Parent SNAP-ADHD, Mean ± SD*   
3 p.m. (average) 0.6 ± -0.4 0.4 ± 0.3 
6 p.m. (average) 0.7 ± 0.6 0.7 ± 0.6 
3 p.m. Office Math Test, Mean Correct ± SD* 122.9 ± 57.7 120.1 ± 59.5 
6 p.m. Home Math Test, Mean Correct ± SD* 121.2 ± 55.4 120.8 ± 64.4 
Patients taking 10 mg d-MPH b.i.d., n (%) 24 (70.6) 32 (80.0) 
Table 2. Baseline (Visit 8, end of part A, beginning of double-blind placebo discontinuation) Demographic 
and clinical characteristics of subjects randomized in part B 
Demographic and baseline clinical characteristics for the 2-week, double-blind, randomized, 
placebo-controlled withdrawal group (Part B). By this point (i.e., following 6 weeks of open treatment with 
d-MPH), most patients demonstrated mild to no ADHD behavioral symptoms (88.6% of patients 
subsequently randomized to d-MPH; 87.5% of patients subsequently randomized to placebo). 
d-MPH, d-methylphenidate; SD, standard deviation; ADHD, attention deficit hyperactivity 
disorder; CGI-S, Clinical Global Impression—Severity of Illness Scale; SNAP-ADHD, Swanson, Nolan, 
and Pelham—Attention Deficit Hyperactivity Disorder symptom scale. 
*Ns varied according to outcome measure. 
Doses 
Most patients (86.5%) started d-MPH at 2.5 mg twice-daily. With weekly dose 
escalation, 83.9% of patients took 5 mg twice-daily after 1 week and 70.2% of patients took 10 
mg twice-daily after the 2nd week. Most patients were maintained on 10 mg twice-daily for the 
remainder of Part A. At the baseline visit of the withdrawal phase (Part B), 70.6% and 80.0% of 
d-MPH and placebo patients, respectively, were dispensed doses of 10 mg twice-daily. At the 
last visit of Part B, 68.6% of d-MPH continuers and 79.5% of placebo patients were ostensibly 
receiving 10 mg twice-daily. 
Efficacy 
Results for primary and secondary efficacy variables are listed in Table 3. There were 
significantly more treatment failures (CGI-I of 6 or 7, much worse or very much worse) at the 
end of Part B in the placebo group than in the d-MPH group (61.5% versus 17.1%; p = 0.001). 
Even if treatment failure were redefined to include the score of 5 (slightly worse) on the CGI-I, 
there were still significantly more treatment failures (CGI-I of 5, 6, or 7) in the placebo group 
than in the d-MPH group (71.8% versus 45.8%; p = 0.0235). Baseline illness severity was not 
predictive of medication response. There was also significantly more deterioration in the 6 p.m. 
Math Test for placebo patients (mean of 17.2 fewer correct answers, compared to 1.2 fewer for 
d-MPH patients, p < 0.0001), demonstrating a 6-hour duration of significant benefit. 
Endpoint measure* d-MPH Placebo P value 
CGI-I Scores of 6 or 7    
End of 1 week of Part B, n (%) 5/35 (14.3) 22/40 (55.0) __ 
Treatment failure** (end of 2 weeks), n (%) 6/35 (17.1) 24/39 (61.5) 0.0010 
Teacher SNAP-ADHD 
   
Baseline (Visit 8,end of Part A), Mean ± SD 0.7 ± 0.7 0.7 ± 0.7 __ 
End of withdrawal phase (Visit 10), Mean ± SD 0.7 ± 0.7 1.4 ± 0.9 __ 
Change from baseline, Mean ± SD† 0 ± 0.7 0.7 ± 0.8 0.028 
Parent SNAP-ADHD, 3 p.m. 
   
Baseline (Visit 8, end of Part A), Mean ± SD 0.6 ± 0.4 0.4 ± 0.3 __ 
End of withdrawal phase (Visit 10), Mean ± SD 0.8 ± 0.7 1.3 ± 0.9 __ 
Change from baseline, Mean ± SD† 0.2 ± 0.6 0.8 ± 0.8 0.0026 
Parent SNAP-ADHD, 6 p.m. 
   
Baseline (Visit 8, end of Part A), Mean ± SD 0.7 ± 0.6 0.7 ± 0.6 __ 
End of withdrawal phase (Visit 10), Mean ± SD 0.9 ± 0.7 1.4 ± 1.0 __ 
Change from baseline, Mean ± SD† 0.1 ± 0.5 0.6 ± 0.8 0.0381 
Deterioration on Math Test, Mean ± SD‡ 
   
Office-based 2-3 p.m. 0.9 ± 16.9 -11.7 ± 22.0 0.024 
Home-based 6 p.m. -1.2 ± 17.5 -17.2 ± 35.6 <0.0001 
Table 3. Results from double-blind withdrawal phase (part B) 
Results for efficacy variables. Overall, the placebo group experienced significantly more treatment 
failures than the d-MPH group at the end of Part B, including deterioration in the 6 p.m. Math Test and the 
Teacher SNAP-ADHD and both the 3 p.m. and 6 p.m. Parent SNAP-ADHD scores. 
d-MPH, d-methylphenidate; SNAP-ADHD, Swanson, Nolan, and Pelham–Attention Deficit 
Hyperactivity Disorder symptom scale; SD, standard deviation. 
*Ns varied according to outcome measure. 
†Mean change from baseline (Visit 8) to the end of the double-blind phase (Visit 10). 
‡Mean change from average Visits 7 and 8 compared with average Visits 9 and 10. 
** Treatment failure = Clinical Global Impression—Improvement Scale (CGI-I) of 6 or 7 at end 
of 2-week withdrawal phase compared to end of 6 weeks of open treatment. 
During Part B, placebo patients showed a significant deterioration from baseline in 
performance versus d-MPH patients on all secondary efficacy variables, including the Teacher 
SNAP-ADHD (p = 0.028) and both the 3 p.m. and 6 p.m. Parent SNAP-ADHD scores (Fig. 1; p 
= 0.0026 and p = 0.0381, respectively). 
On the clinic-based 2 p.m.–3 p.m. Math Test, placebo patients demonstrated a mean of 
11.7 fewer correct answers than at baseline versus a mean of 0.9 more correct answers by d-
MPH patients (p = 0.024). For all efficacy variables, d-MPH patients continued to demonstrate 
the stable benefit obtained during the open-label titration phase, and the magnitude of the effect 
at 6 hours after the noon dose was similar to the effect at 3 hours (Table 3 and Fig. 1). 
In reference to additional efficacy variables, of 74 patients who had CGI ratings at the 
final open-label titration phase Part A visit, 73 patients (98.6%) were classified as responders 
based on a CGI-I score of “very much improved” or “much improved.” Significant improvement 
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In Part B, approximately 46% of d-MPH patients and 38% of placebo patients 
experienced at least one AE, which were generally mild. Abdominal pain and headache were the 
most common. Insomnia, known to be associated with stimulant use, was reported only in 
patients receiving placebo; headache incidence also was greater in placebo patients. No patient 
experienced an AE judged both severe and treatment-related. No patient discontinued the study 
because of an AE during this phase, and no dosage reductions were required for AEs. Abrupt d-
MPH discontinuation at the start of the randomized withdrawal phase was not associated with 
drug-related rebound or withdrawal symptoms.  
AE. n (%) 
Part A: open-label 
titration 
n = 89 
Part B: 
Double-Blind 
withdrawal 
d-MPH 
n = 35 
Placebo 
n = 40 
Headache 24 (27.0) 2 (5.7) 3 (7.5) 
Viral infection 18 (20.2) 0 0 
Anorexia 16 (18.0) 0 0 
Insomnia 16 (18.0) 0 2 (5.0) 
Abdominal pain 15 (16.9) 3 (8.6) 0 
Accidental injury 10 (11.2) 0 0 
Pharyngitis 10 (11.2) 0 0 
Asthenia 7 (7.9) 0 0 
Fever 7 (7.9) 0 0 
Nausea 7 (7.9) 0 0 
Cough increased 7 (7.9) 2 (5.7) 0 
Dyspepsia 6 (6.7) 0 0 
Rash 6 (6.7) 0 0 
Rhinitis 5 (5.6) 0 2 (5.0) 
Pain 3 (3.4) 0 2 (5.0) 
Vomiting 3 (3.4) 0 0 
Weight loss 3 (3.4) 0 0 
Chest pain 0 2 (5.7) 0 
Gastroenteritis 0 0 0 
Sinusitis 0 0 0 
Otitis media 0 0 0 
Table 4. Adverse events that occurred in at least 5% of patients in any one treatment group: Study phases 
A and B 
Adverse events that occurred during treatment. Although 77 of the 89 patients (86.5%) experienced one or 
more AE during Part A, no deaths or serious treatment-related AEs occurred. Dosage reductions resolved most AEs. 
AE, adverse event; d-MPH, d-methylphenidate. 
Clinically trivial mean increases in pulse rate (PR) and blood pressure (BP) were noted in 
both treatment groups in relation to baseline. A few PR and BP changes met technical criteria for 
clinically significant change, but most of these were lower and benign (exceptions noted below). 
• During Part A, mean systolic BP (SBP) rose 2.6 ± 10.8 mm Hg, diastolic BP (DBP) rose 
0.86 ± 0.8 mm Hg, and PR rose 3.7 ± 12.7 bpm, as would be expected with stimulant 
treatment. Three patients had transient hypertension and 2 patients had transient increases 
of PR to 120 bpm. 
• During Part B, the BP rise from original baseline was nominally lower in d-MPH versus 
placebo patients (SBP 2.6 ± 11.6 versus 3.1 ± 9.5; DBP 0.0 ± 7.1 versus 0.2 ± 6.8). PR 
increase from original baseline was 5.4 ± 12.2 (versus 1.9 ± 10.7 in the placebo group). 
There was no evidence of clinically significant treatment-related changes in hematologic 
or blood-chemistry parameters. 
Discussion 
This study evaluated the safety, efficacy, and duration of effect of d-MPH in maintaining 
improvement in ADHD in children who respond to this agent. Efficacy data are based on 75 
patients randomized to d-MPH or placebo during Part B. 
Patients receiving d-MPH in doses of 5–20 mg/day in Part A showed substantial 
improvement from baseline. The parent and teacher SNAP-ADHD mean ratings of 0.6–0.8 are 
essentially normal. These mean item ratings are between “no symptom at all” and “just a little.” 
The National Institute of Mental Health (NIMH) Multimodal Treatment Study of Children with 
ADHD (MTA) used a SNAP item mean of 1.0 or less as a measure of normalization (Swanson et 
al. 2001). The CGI-S ratings at 6 weeks were consistent with the parent and teacher ratings: 
89.2% of patients were mildly ill, borderline ill, or normal, compared to only 1.1% at baseline. 
During Part B, the proportion of treatment failures in the placebo group (61.5%) was 3.6 
times as great as in the d-MPH group (17.1%; p = 0.001). Behavioral scores based on the 
Teacher and Parent SNAP-ADHD also deteriorated significantly in placebo-treated, but not d-
MPH–treated, patients during this phase. In fact, patients maintained on d-MPH throughout Part 
B had no or mild behavioral symptoms on Parent and Teacher SNAP-ADHD tests measured both 
3 and 6 hours after taking d-MPH. CGI scores in this group also remained generally stable, 
maintaining the improvement from original baseline noted at the start of Part B. A dramatic 
clinical improvement in the placebo-treated patients was observed following the resumption of d-
MPH treatment in the open extension. 
Of considerable interest is d-MPH’s duration of action of at least 6 hours, supported by 
differences between the treatment and placebo groups (favoring d-MPH) in the 6-hour post-dose 
weekend Math Test and the 6-hour postdose Parent SNAP-ADHD scores. The behavioral scores 
based on the Teacher and Parent SNAP-ADHD were consistent with children having no or 
negligible symptoms (SNAP score, <1.0) when measured at both 3 hours (0.7 and 0.8) and 6 
hours (0.85) after taking d-MPH. In contrast, the comparable scores for the placebo group were 
1.2–1.3 and 1.4. The latter scores replicate other reports of placebo-controlled natural 
deterioration in ADHD behavior in the late afternoon (e.g., Wigal et al. 2004). 
AEs were consistent with those of other stimulant medications. No serious AEs were 
considered treatment-related (one serious AE—an accidental injury—occurred during Part B and 
was considered unrelated to treatment). Data from this study are consistent with the results of the 
earlier randomized, placebo-controlled phase III trial comparing efficacy of d-MPH and d,l-MPH 
over 4 weeks in children with ADHD (Wigal et al. 2004). In that study, the Teacher SNAP-
ADHD score, the primary efficacy variable, was significantly improved by both active 
treatments versus placebo. Both active drugs also improved the secondary measures of CGI-I, 
Parent 3 p.m. SNAP-ADHD, and 3 p.m. Math Test versus placebo. However, only d-MPH 
improved Parent SNAP-ADHD and Math Test scores at 6 hours postdosing, demonstrating a 
nominally longer duration of efficacy than d,l-MPH, which showed a nonsignificant tendency in 
the same direction, compared to placebo. The data from this study confirm a duration of efficacy 
of at least 6 hours for d-MPH after the 2nd daily dose. 
The randomized withdrawal approach used in this study is especially suitable for drugs 
such as d-MPH that can suppress symptoms or signs of a chronic illness (U.S. Department of 
Health and Human Services 2001). The withdrawal study becomes, in effect, a relapse-
prevention trial. This design is appropriate for ADHD, in which long-term, placebo-controlled 
trials would be especially difficult for patient and caregiver. When used with an early-escape 
endpoint, the period of exposure to placebo with poor response is minimized. Prompt monitoring 
of study endpoints ensures that treatment failures are rapidly identified. 
This study design has some potential limitations. Patients could develop withdrawal signs 
or symptoms, although none were noted. There is a scientific risk that the expected deterioration 
on placebo may not occur, at least not as quickly as anticipated. Although it is widely accepted 
that withdrawal of stimulant in ADHD precipitates prompt relapse, the published documentation 
is less abundant than the belief, and some reports actually suggest the contrary (e.g., Gillberg et 
al. 1997; Abikoff and Gittelman 1985). More importantly, treatment effects in such trials may be 
larger than those seen in unselected populations, because the randomized withdrawal phase 
preselected responders to the drug from the open-label titration phase (U.S. Department of 
Health and Human Services 2001). The result is similar to, but the mechanism different from, the 
increase in evident placebo-controlled responders after a placebo washout. In both cases, the 
difference between placebo and active treatment is enhanced: With a placebo washout, placebo 
responders are eliminated, reducing the number of placebo responders in the randomized sample; 
in contrast, with a discontinuation study of responders, nonresponders are eliminated before 
randomization. Those who were randomized in Part B included placebo responders and true 
responders, but not nonresponders. On the other hand, the tendency for placebo discontinuation 
studies to inflate the responder rate may be neutralized, to some extent, by “negative placebo 
effect,” in which parent and teacher ratings of a child continuing active treatment may deteriorate 
from the knowledge that the child might be having helpful treatment withdrawn. This 
phenomenon is illustrated in Fig. 1, showing that the double-blind parent ratings worsened for 
both placebo and active d-MPH at both 3 p.m. and 6 p.m., although significantly less for d-MPH. 
Note that the same phenomenon is not nearly as apparent in the more objective Math Tests 
(Table 3). 
Another possible limitation is the duration of the discontinuation (2 weeks). Abikoff and 
Gittelman (1985) noted in a placebo discontinuation after 16 weeks of d,l-MPH treatment that it 
took over 2 weeks, on average, for patients to deteriorate enough on placebo to need 
remedication. Conceivably, the proportion of relapses on placebo might have been greater if the 
discontinuation had been extended for another week. However, comparison of the proportion of 
relapsers in weeks 1 and 2 of this study suggests that a plateau had been reached by week 2. 
A possible criticism of the statistical analyses is that the Bonferroni correction for 
multiple tests was not used. One might argue that with 6 outcome tests for Part B, the required 
significance level should be divided by 6. A more realistic argument would be that each domain 
with multiple measures should have such correction: behavior ratings (3 measures) divided by 3 
and objective Math Test (2 measures) divided by 2. However, with the two critical outcome 
measures significant at 0.001 (percent treatment failure) and <0.0001 (6 p.m. Math Test), and 
with all measures showing a large effect size, the issue seems moot. 
Conclusions 
In summary, this study confirms earlier observations that the d-enantiomer of d,l-MPH is 
effective in the treatment of childhood ADHD, and that there is no need to compensate for the 
loss of l-enantiomer “activity.” This observation contrasts with amphetamine, in which both 
enantiomers are approximately equipotent for behavioral benefit (Arnold et al. 1972; Arnold et 
al. 1976). 
More importantly for clinicians, this study demonstrates a duration of effect of at least 6 
hours. This effect allows for an additional option besides the usually quoted 4-hour duration of 
immediate-release d,l-MPH and the long-acting bead or osmotic tablet preparations. 
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